Oncological Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Monica A. Fallon, Erik B. Gerlach, Jack Siqueiros, Jón T. Njarðarson
Purinethol Methotrexate Myleran Leukeran Cytoxan Fluorouracil Oncovin Cosmegen Alkeran Velban Vercyte Thioguanine Imuran Cytosar-U Matulane Lysodren Megace Blenoxane Adriamycin RDF DTIC-Dome Amsacrine ( Mercaptopurine ) ( Methotrexate ) ( Busulfan ) ( Chlorambucil ) ( Cyclophosphamide ) ( Fluorouracil ) ( Vincristine ) ( Dactinomycin ) ( Melphalan ) ( Vinblastine ) ( Pipobroman ) ( Thioguanine ) ( Azathioprine ) ( Cytarabine ) ( Procarbazine ) ( Mitotane ) ( Megestrol ) ( Bleomycin ) ( Doxorubicin ) ( Dacarbazine ) ( Amsacrine )
NLY/CLE/BLE* BLE/BRE/HEA/NEC/TLY/NLY* MYELOID LEUKEMIA CLE/NLY/HLY/TES/OUT/RTU* BREAST CANCER COLORECTAL CANCER MULTIPLE MYELOMA TESTICULAR CANCER MULTIPLE MYELOMA HODGKIN LYMPHOMA BREAST CANCER MLE/NLE/ELE/BLE* GRAFT-VERSUS-HOST-DISEASE MLE/NLY* HODGKIN LYMPHOMA BRAIN TUMORS BRE/END* HODGKIN LYMPHOMA NLY/HLY/MLE/BRE/GAS/OVA/SCL/THY/BLA* MELANOMA LYMPHOBLASTIC LEUKEMIA Approved 1953 Approved 1953 Approved 1954 Approved 1957 Approved 1959 Approved 1962 Approved 1963 Approved 1964 Approved 1964 Approved 1965 Approved 1966 Approved 1966 Approved 1968 Approved 1969 Approved 1969 Approved 1970 Approved 1971 Approved 1973 Approved 1974 Approved 1975 Approved 1976
CeeNU BiCNU Nolvadex Platinol Cerubidine Cytadren Emcyt Mutamycin Zanosar Vindesine VePesid Novantrone Ifex Paraplatin Eulexin Hexalen Idamycin DES Fludara Nipent Masoprocol ( Lomustine ) ( Carmustine ) ( Tamoxifen ) ( Cisplatin ) ( Daunorubicin ) ( Aminoglutethimide ) ( Estramustine ) ( Mitomycin ) ( Streptozocin ) ( Vindesine ) ( Etoposide ) ( Mitoxantrone ) ( Ifosfamide ) ( Carboplatin ) ( Flutamide ) ( Altretamine ) ( Idarubicin ) ( Diethylstilbestrol ) ( Fludarabine ) ( Pentostatin ) ( Masoprocol )
HODGKIN LYMPHOMA BTU/MUM/NLY* BREAST CANCER TES/OVA* MLE/BLY* BREAST CANCER PROSTATE CANCER BLA/ALA/COL* HLY/PTU/CTU* HLY/MLE/MEL/BRE/NCL* SMALL CELL LUNG CANCER MLE/NLY/PRO/BRE* TESTICULAR CANCER OVARIAN CANCER PROSTATE CANCER OVARIAN CANCER MYELOID LEUKEMIA BRE/PRO* CLE/NLY* HAIRY CELL LEUKEMIA SKIN CANCER Approved 1976 Approved 1977 Approved 1977 Approved 1978 Approved 1979 Approved 1980 Approved 1981 Approved 1981 Approved 1982 Approved 1982 Approved 1983 Approved 1987 Approved 1988 Approved 1989 Approved 1989 Approved 1990 Approved 1990 Approved 1990s Approved 1991 Approved 1991 Approved 1992
Taxol Vumon Leustatin Prograf Ethyol Arimidex Casodex Intron A Photofrin Leukine Anexsia Taxotere Gemzar Zoladex Visipaque Camptosar Lupon Depot Kadian Nilandron Aredia Hycamtin ( Paclitaxel ) ( Teniposide ) ( Cladribine ) ( Tacrolimus ) ( Amifostine ) ( Anastrozole ) ( Bicalutamide ) ( Interferon Alfa-2b ) ( Porfimer ) ( Sargramostim ) ( Acetaminophen & Hydrocodone ) ( Docetaxel ) ( Gemcitabine ) ( Goserelin ) ( Iodixanol ) ( Irinotecan ) ( Leuprolide ) ( Morphine ) ( Nilutamide ) ( Pamidronate ) ( Topotecan )
BREAST CANCER CLE/SCL* NLY/CLE/HLE* GRAFT-VERSUS-HOST DISEASE CHEM. IND. NAUSEA & VOMITING BREAST CANCER PROSTATE CANCER MEL/HLE/HLY* ESOPHAGEAL CANCER MYELOID LEUKEMIA OPIOD ANALGESIC BREAST CANCER NCL/PAN* PROSTATE CANCER CONTRAST AGENT COLORECTAL CANCER PROSTATE CANCER OPIOD ANALGESIC PROSTATE CANCER HYPERCALCEMIA NON-SMALL CELL LUNG CARCIN Approved 1992 Approved 1992 Approved 1993 Approved 1994 Approved 1995 Approved 1995 Approved 1995 Approved 1995 Approved 1995 Approved 1995 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996
Agrylin Xibrom Anzemet Kytril Aldara Femara Neumega Rituxan Quadramet Fareston Proleukin Xeloda Celebrex Actiq Arava Zofran Prometrium Tomudex Thalomid Herceptin Valstar ( Anagrelide ) ( Bromfenac ) ( Dolasetron ) ( Granisetron ) ( Imiquimod ) ( Letrozole ) ( Oprelvekin ) ( Rituximab ) ( Samarium Sm 153 Lexidronam ) ( Toremifene ) ( Aldesleukin ) ( Capecitabine ) ( Celecoxib ) ( Fentanyl ) ( Leflunomide ) ( Ondansetron ) ( Progesterone ) ( Raltitrexed ) ( Thalidomide ) ( Trastuzumab ) ( Valrubicin )
MYELOID LEUKEMIA OPIOD ANALGESIC CHEM. IND. NAUSEA & VOMITING CHEM. IND. NAUSEA & VOMITING BASAL CELL CARCINOMA BREAST CANCER THROMBOCYTOPENIA NON HODGKIN LYMPHOMA BONE CANCER BREAST CANCER MEL/KID* BREAST CANCER OPIOID ANALGESIC OPIOID ANALGESIC MYELOID LEUKEMIA CHEM. IND. NAUSEA & VOMITING BREAST CANCER COLORECTAL CANCER MULTIPLE MYELOMA BREAST CANCER BLADDER CANCER Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998
Alitretinoin Levulan Targretin Ellence Aromasin Uvadex Rapamune Temodar Navelbine Trisenox Mylotarg Trelstar Depot Campath Gleevec Zometa Faslodex Zevalin Eloxatin Eloxatin Neulasta SecreFlo ( Alitretinoin ) ( Aminolevulinic Acid ) ( Bexarotene ) ( Epirubicin ) ( Exemestane ) ( Methoxsalen ) ( Sirolimus ) ( Temozolomide ) ( Vinorelbine ) ( Arsenic Trioxide ) ( Gemtuzumab Ozogamicin ) ( Triptorelin ) ( Alemtuzumab ) ( Imatinib ) ( Zoledronic Acid ) ( Fulvestrant ) ( Ibritumomab Tiuxetan ) ( Oxaliplatin ) ( Oxaliplatin, 5-Fluorouracil, & Leucovorin ) ( Pegfilgrastim ) ( Secretin )
SKIN CANCER SKIN CANCER TLY/BRE/SKI* BREAST CANCER BREAST CANCER T-CELL LYMPHOMA GRAFT-VERSUS-HOST DISEASE BRAIN TUMORS NCL/BRE* MYELOID LEUKEMIA MYELOID LEUKEMIA PROSTATE CANCER LYMPHOCYTIC LEUKEMIA MLE/GTU* MULTIPLE MYELOMA BREAST CANCER NON HODGKIN LYMPHOMA COLORECTAL CANCER COLORECTAL CANCER LEUKOCYTE GROWTH FACTOR PANCREATIC CANCER Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Approved 2000 Approved 2000 Approved 2000 Approved 2001 Approved 2001 Approved 2001 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002
Plenaxis UroXatral Emend Velcade Premarin Iressa Aloxi Bexxar Avastin Erbitux Sensipar Clolar Tarceva Metvixia Myfortic Kepivance Alimta Arranon Nexavar Sprycel Vectibix ( Abarelix ) ( Alfuzosin ) ( Aprepitant ) ( Bortezomib ) ( Conjugated Estrogens ) ( Gefitinib ) ( Palonosetron ) ( Tositumomab ) ( Bevacizumab ) ( Cetuximab ) ( Cinacalcet ) ( Clofarabine ) ( Erlotinib ) ( Methyl Aminolevulinate ) ( Mycophenolic Acid ) ( Palifermin ) ( Pemetrexed ) ( Nelarabine ) ( Sorafenib ) ( Dasatinib ) ( Panitumumab )
PROSTATE CANCER PROSTATE CANCER CHEM. IND. NAUSEA & VOMITING MUM/MLY* BREAST CANCER NON-SMALL CELL LUNG CARCIN CHEM. IND. NAUSEA & VOMITING NON HODGKIN LYMPHOMA COL/NCL/BRE/BTU/KID/OVA* COLORECTAL CANCER PARATHYROID CARCINOMA LYMPHOBLASTIC LEUKEMIA PANCREATIC CANCER SKIN CANCER GRAFT-VERSUS HOST DISEASE BLO/BMA* NCL/MES* BLE/BLY* KIDNEY CANCER MLE/BLE* COLORECTAL CANCER Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2005 Approved 2005 Approved 2006 Approved 2006
Oncaspar Gardasil Sutent Zolinza Ixempra Tykerb Tasigna Evista Torisel Treanda Degarelix Fusilev Mozobil Nplate Afinitor Arzerra Votrient Folotyn Elitek Istodax Jevtana ( Pegaspargase ) ( Quadrivalent Human Papillomavirus Vaccine ) ( Sunitinib ) ( Vorinostat ) ( Ixabepilone ) ( Lapatinib ) ( Nilotinib ) ( Raloxifene ) ( Temsirolimus ) ( Bendamustine ) ( Degarelix ) ( Folinic Acid ) ( Plerixafor ) ( Romiplostim ) ( Everolimus ) ( Ofatumumab ) ( Pazopanib ) ( Pralatrexate ) ( Rasburicase ) ( Romidepsin ) ( Cabazitaxel )
CLE/NLY/BLY/MLE* CER/ANA* KIDNEY CANCER T-CELL LYMPHOMA BREAST CANCER BREAST CANCER MYELOID LEUKEMIA BREAST CANCER KIDNEY CANCER LYMPHOCYTIC LEUKEMIA PROSTATE CANCER BONE CANCER MULTIPLE MYELOMA THROMBOCYTOPENIA KID/PAN/BRE* LYMPHOCYTIC LEUKEMIA OVARIAN CANCER T-CELL LYMPHOMA TUMOR LYSIS SYNDROME T-CELL LYMPHOMA PROSTATE CANCER Approved 2006 Approved 2006 Approved 2006 Approved 2006 Approved 2007 Approved 2007 Approved 2007 Approved 2007 Approved 2007 Approved 2008 Approved 2008 Approved 2008 Approved 2008 Approved 2008 Approved 2009 Approved 2009 Approved 2009 Approved 2009 Approved 2009 Approved 2009 Approved 2010
Xgeva Halaven Provenge Zytiga Erwinaze Adcretris Xalkori Yervoy Sylatron Jakafi Vandetanib Zelboraf Inlyta Bosulif Cometriq Kyprolis Xtandi Voraxaze Picato Synribo Perjeta ( Denosumab ) ( Eribulin ) ( Sipuleucel-T ) ( Abiraterone ) ( Asparaginase Erwinia Chrysanthemi ) ( Brentuximab Vedotin ) ( Crizotinib ) ( Ipilimumab ) ( Peginterferon Alfa-2b ) ( Ruxolitinib ) ( Vandetanib ) ( Vemurafenib ) ( Axitinib ) ( Bosutinib ) ( Cabozantinib ) ( Carfilzomib ) ( Enzalutamide ) ( Glucarpidase ) ( Ingenol Mebutate ) ( Omacetaxine ) ( Pertuzumab )
MULTIPLE MYELOMA BREAST CANCER PROSTATE CANCER PROSTATE CANCER LYMPHOBLASTIC LEUKEMIA HODGKIN LYMPHOMA NON-SMALL CELL LUNG CARCIN MELANOMA MELANOMA BONE MARROW CANCER THYROID CANCER MELANOMA KIDNEY CANCER MYELOID LEUKEMIA THYROID CANCER MULTIPLE MYELOMA PROSTATE CANCER KIDNEY CANCER SKIN CANCER MYELOID LEUKEMIA BREAST CANCER Approved 2010 Approved 2010 Approved 2010 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2011 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012
Iclusig Stivarga Neutroval Erivedge BEP BEACOPP CAPOX CHOP CMF CVP C-VAMP COPP ADE AC ABVD ABVE ABVE-PC AC-T EPOCH FU-LV Gemcitabine/Cisplatin ( Ponatinib ) ( Regorafenib ) ( tbo-Filgrastim ) ( Vismodegib ) ( Bleomycin, Etoposide & Cisplatin ) ( Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine & Prednisone ) ( Capecitabine & Oxaliplatin ) ( Cyclophosphamide, Doxorubicin, Vincristine & Prednisone ) ( Cyclophosphamide, Methotrexate & Fluorouracil ) ( Cyclophosphamide, Vincristine, & Prednisone ) ( Cyclophosphamide, Vincristine, Doxorubicin & Methylprednisolone ) ( Cyclophosphamide, Vincristine, Procarbazine & Prednisone ) ( Cytabarine, Daunorubicin & Etoposide ) ( Doxorubicin & Cyclophosphamide ) ( Doxorubicin, Bleomycin, Vinblastine & Dacarbazine ) ( Doxorubicin, Bleomycin, Vincristine & Etoposide ) ( Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone & Cyclophosphamide ) ( Doxorubicin, Cyclophosphamide & Paclitaxel ) ( Etoposide, Prednisone, Vincristine, Cyclophosphamide & Doxorubicin ) ( Fluorouracil & Leucovorin ) ( Gemcitabine & Cisplatin )
MYELOID LEUKEMIA COLORECTAL CANCER CHEM. IND. NAUSEA & VOMITING SKI/COL* OVA/TES* HODGKIN LYMPHOMA COLORECTAL CANCER NON HODGKIN LYMPHOMA BREAST CANCER NLY/MLE* KIDNEY CANCER HLY/NLY* MYELOID LEUKEMIA BREAST CANCER HODGKIN LYMPHOMA HODGKIN LYMPHOMA HODGKIN LYMPHOMA BREAST CANCER NON HODGKIN LYMPHOMA COL/ESO/GAS* BIL/BLA/CER/MES/NCL/OVA/PAN* Approved 2012 Approved 2012 Approved 2012 Approved 2012 Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+
ICE FOLFIRI FOLFOX FOLFIRI-Bevacizumab FOLFIRI-Cetuximab FOLFIRINOX Stanford V MOPP R-CHOP R-CVP VeIP VAMP SUBCATEGORY ABBREVIATIONS ( Ifosfamide, Carboplatin & Etoposide ) ( Leucovorin, Fluorouracil & Irinotecan) ( Leucovorin, Fluorouracil & Oxaliplatin ) ( Leucovorin, Fluorouracil, Irinotecan & Bevacizumab ) ( Leucovorin, Fluorouracil, Irinotecan & Cetuximab ) ( Leucovorin, Fluorouracil, Irinotecan & Oxaliplatin ) ( Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide & Prednisone ) ( Mechloroethamine, Vincristine, Prednisone & Procarbazine ) ( Rituximab, Cyclophosphamide, Doxorubicin, Vincristine & Prednisone ) ( Rituximab, Cyclophosphamide, Vincristine & Prednisone ) ( Vinblastine, Ifosfamide, Cisplatin & Mesna ) ( Vincristine, Doxorubicin, Methotrexate & Prednisone ) ANA Anal Cancer ESO Esophageal Cancer MUM Multiple Myeloma BLE Basophilic Leukemia GAS Gastric Cancer MLE Myeloid Leukemia BIL Biliary Tract Cancer GTU Gastrointestinal Tumors NEC Neck Cancer BLA Bladder Cancer HLE Hairy Cell Leukemia NLE Neutrophilic Leukemia BLO Blood Cancer HEA Head Cancer NCL Non Small Cell Lung Carcinoma BMA Bone Marrow Cancer HLY Hodgkin Lymphoma OVA Ovarian Cancer BTU Brain Tumors KID Kidney Cancer PAN Pancreatic Cancer RTU Breast Tumors BLE Lymphoblastic Leukemia PTU Pancreatic Tumors CER Cervical Cancer BLY Lymphoblastic Lymphoma PRO Prostate Cancer COL Colorectal Cancer CLE Lymphocytic Leukemia SKI Skin Cancer CTU Colorectal Tumors MLY Mantle Cell Lymphoma SCL Small Cell Lung Cancer HLY/NLY* COLORECTAL CANCER COLORECTAL CANCER COLORECTAL CANCER COLORECTAL CANCER PANCREATIC CANCER HODGKIN LYMPHOMA HODGKIN LYMPHOMA NON HODGKIN LYMPHOMA NON HODGKIN LYMPHOMA OVA/TES* HODGKIN LYMPHOMA END Endometerial Cancer MEL Melanoma TLY T-Cell Lymphoma Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ Not Approved+ ELE Eosinophilic Leukemia MES Mesothelioma TES Testicular Cancer
All drugs are considered FDA approved in the U.S. following the passage of the Pure Food and Drugs Act in 1906. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ * The FDA approval year and Market Name is representative of the first three-letter abbreviation of an oncological condition (see legend) in the series. This drug has also been FDA approved for additional disorders. + According to the National Cancer Institute (http://www.cancer.gov), chemotherapy regimens do not have an official FDA approval, however, each individual molecular component is FDA approved.